CareDx, Inc. reported a significant increase in its financial performance for the third quarter of 2025, with total revenue reaching $100.1 million, a 21% increase compared to $82.9 million in the same period last year. The growth was driven by a 19% rise in testing services revenue, which amounted to $72.2 million, and a 30% increase in patient and digital solutions revenue, totaling $15.4 million. The company also recorded a net income of $1.7 million, a notable turnaround from a net loss of $10.6 million in the third quarter of 2024.
In terms of operational metrics, CareDx reported a testing services volume of 50,300, reflecting a 13% increase year-over-year. The company’s product revenue also saw a 22% increase, reaching $12.5 million, attributed to higher sales of its genomic-based solutions. The overall revenue growth was supported by improved collections and revenue recognition from prior periods, as outlined in the company’s financial statements.
CareDx has made strategic moves to enhance its market position, including the implementation of a stock repurchase program. In the first nine months of 2025, the company repurchased 5 million shares for a total of $75.6 million. Additionally, the company has been focusing on expanding its digital solutions, with increased customer adoption of its Ottr software and pharmacy services contributing to the growth in patient and digital solutions revenue.
Despite the positive financial results, CareDx reported an accumulated deficit of $719 million as of September 30, 2025. The company’s cash, cash equivalents, and marketable securities totaled $194.2 million, reflecting a decrease from the previous quarter, primarily due to the stock repurchase activities. Looking ahead, CareDx anticipates that its existing cash balance and expected cash from operations will be sufficient to meet its anticipated cash requirements for the next 12 months.
The company continues to face challenges, including a material weakness in its internal control over financial reporting, which management is actively working to remediate. CareDx has implemented training and updated its internal accounting policies to strengthen its control environment. The company remains committed to maintaining a robust internal control framework while pursuing growth opportunities in the transplantation diagnostics market.
About CareDx, Inc.
CareDx is a precision medicine company specializing in the discovery, development, and commercialization of high-value diagnostic solutions for transplant patients. Its core offerings include molecular diagnostic tests, digital patient management tools, and lab products that improve transplant outcomes. Serving transplant centers and healthcare providers primarily in the U.S. and Europe, CareDx leverages genomic technologies and data-driven solutions to enhance organ rejection detection, patient monitoring, and operational efficiency.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.